Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

1.1 Translating the therapeutic potential of the epicardium

  1. Characterisation of the full tissue-resident potential of activated adult epicardial cells (EPDCs)
  2. Lead candidate small-molecule-activators of human EPDCs via high throughput phenotypic screening (HTS) and drug discovery
  3. Generation of GMP hESC- epicardium (with UKRMP)
  4. Development of functional vascularised patches for treatment of impaired LV function post-MI






1.2 Identifying targets to induce neovascularisation, collateral growth and vascular support

  1. Identification and functional characterisation of novel cellular sources of new coronary blood and lymphatic vessels post-MI
  2. Insight into the gene regulatory networks which determine neovascularisation post-MI and identification of therapeutic regulators of coronary endothelium
  3. Small molecule leads for induction of coronary endothelial cells (ECs) from a human ESC-derived endocardium model
  4. Identification and evaluation of vascular smooth muscle cell (VSMC) responses post-MI and strategies to augment VSMC proliferation to improve collateral support of new vessel formation from 1) above.

Our Team